SG11202100028PA - METHOD FOR THE PRODUCTION OF FREEZE-DRIED PELLETS COMPRISING AN ANTI-COAGULATION FACTOR XIa (FXIa) ANTIBODY - Google Patents

METHOD FOR THE PRODUCTION OF FREEZE-DRIED PELLETS COMPRISING AN ANTI-COAGULATION FACTOR XIa (FXIa) ANTIBODY

Info

Publication number
SG11202100028PA
SG11202100028PA SG11202100028PA SG11202100028PA SG11202100028PA SG 11202100028P A SG11202100028P A SG 11202100028PA SG 11202100028P A SG11202100028P A SG 11202100028PA SG 11202100028P A SG11202100028P A SG 11202100028PA SG 11202100028P A SG11202100028P A SG 11202100028PA
Authority
SG
Singapore
Prior art keywords
fxia
freeze
antibody
production
coagulation factor
Prior art date
Application number
SG11202100028PA
Inventor
Stefan Schneid
Stefan Heke
Matthias Plitzko
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of SG11202100028PA publication Critical patent/SG11202100028PA/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/36—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against blood coagulation factors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • F—MECHANICAL ENGINEERING; LIGHTING; HEATING; WEAPONS; BLASTING
    • F26—DRYING
    • F26B—DRYING SOLID MATERIALS OR OBJECTS BY REMOVING LIQUID THEREFROM
    • F26B5/00—Drying solid materials or objects by processes not involving the application of heat
    • F26B5/04—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum
    • F26B5/06—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum the process involving freezing
    • F26B5/065—Drying solid materials or objects by processes not involving the application of heat by evaporation or sublimation of moisture under reduced pressure, e.g. in a vacuum the process involving freezing the product to be freeze-dried being sprayed, dispersed or pulverised
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
SG11202100028PA 2018-07-05 2019-07-05 METHOD FOR THE PRODUCTION OF FREEZE-DRIED PELLETS COMPRISING AN ANTI-COAGULATION FACTOR XIa (FXIa) ANTIBODY SG11202100028PA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP2018068250 2018-07-05
PCT/EP2019/068071 WO2020008022A1 (en) 2018-07-05 2019-07-05 METHOD FOR THE PRODUCTION OF FREEZE-DRIED PELLETS COMPRISING AN ANTI-COAGULATION FACTOR XIa (FXIa) ANTIBODY

Publications (1)

Publication Number Publication Date
SG11202100028PA true SG11202100028PA (en) 2021-01-28

Family

ID=67139764

Family Applications (2)

Application Number Title Priority Date Filing Date
SG11202100028PA SG11202100028PA (en) 2018-07-05 2019-07-05 METHOD FOR THE PRODUCTION OF FREEZE-DRIED PELLETS COMPRISING AN ANTI-COAGULATION FACTOR XIa (FXIa) ANTIBODY
SG11202100046UA SG11202100046UA (en) 2018-07-05 2019-07-05 NOVEL STABLE HIGH-CONCENTRATION FORMULATION FOR ANTI-FXIa ANTIBODIES

Family Applications After (1)

Application Number Title Priority Date Filing Date
SG11202100046UA SG11202100046UA (en) 2018-07-05 2019-07-05 NOVEL STABLE HIGH-CONCENTRATION FORMULATION FOR ANTI-FXIa ANTIBODIES

Country Status (15)

Country Link
US (2) US20210290534A1 (en)
EP (2) EP3817723A1 (en)
JP (2) JP2021529800A (en)
KR (2) KR20210028673A (en)
CN (2) CN112543627A (en)
AR (1) AR115713A1 (en)
AU (2) AU2019297498A1 (en)
BR (2) BR112020026492A2 (en)
CA (2) CA3105256A1 (en)
IL (2) IL279868A (en)
MX (2) MX2021000028A (en)
PE (2) PE20210779A1 (en)
SG (2) SG11202100028PA (en)
TW (1) TW202034898A (en)
WO (2) WO2020008022A1 (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112543627A (en) * 2018-07-05 2021-03-23 拜耳公司 Novel stable high concentration anti-FXIa antibody formulations
EP4259200A1 (en) * 2020-12-11 2023-10-18 Boehringer Ingelheim International GmbH Formulation for multi-purpose application

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0859841B1 (en) 1995-08-18 2002-06-19 MorphoSys AG Protein/(poly)peptide libraries
US8703126B2 (en) 2000-10-12 2014-04-22 Genentech, Inc. Reduced-viscosity concentrated protein formulations
JP4829229B2 (en) * 2004-07-23 2011-12-07 バイエル・テクノロジー・サービシーズ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Aseptic freezing, drying, storage, analysis and filling method (SFD-SAF method) (pellet lyophilization method for parenteral biopharmaceuticals)
EP2205280B1 (en) 2007-09-27 2019-09-04 Amgen Inc. Pharmaceutical formulations
EP2578975A1 (en) 2011-10-05 2013-04-10 Sanofi Pasteur Sa Rotary drum freeze-dryer
EP2578974A1 (en) * 2011-10-05 2013-04-10 Sanofi Pasteur Sa Process line for the production of freeze-dried particles
LT2847228T (en) * 2012-05-10 2018-11-12 Bayer Pharma Aktiengesellschaft ANTIBODIES CAPABLE OF BINDING TO THE COAGULATION FACTOR XI AND/OR ITS ACTIVATED FORM FACTOR XIa AND USES THEREOF
US9592297B2 (en) * 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
KR20150070384A (en) 2012-10-25 2015-06-24 메디뮨 엘엘씨 Stable, low viscosity antibody formulation
CN114569716A (en) 2014-10-23 2022-06-03 美国安进公司 Reducing the viscosity of pharmaceutical formulations
EP3167877A1 (en) * 2015-11-12 2017-05-17 Bayer Pharma Aktiengesellschaft Method for the production of freeze-dried pellets comprising factor viii
EP3443346B1 (en) * 2016-04-13 2023-08-30 Medimmune, LLC Use of amino acids as stabilizing compounds in pharmaceutical compositions containing high concentrations of protein-based therapeutic agents
ES2770674T3 (en) * 2016-06-10 2020-07-02 Octapharma Ag High concentration immunoglobulin composition for pharmaceutical applications
EP3559047A1 (en) * 2016-12-23 2019-10-30 Novartis AG Factor xi antibodies and methods of use
CN112543627A (en) * 2018-07-05 2021-03-23 拜耳公司 Novel stable high concentration anti-FXIa antibody formulations

Also Published As

Publication number Publication date
EP3817727A1 (en) 2021-05-12
EP3817723A1 (en) 2021-05-12
KR20210029221A (en) 2021-03-15
JP2021529801A (en) 2021-11-04
BR112020026492A2 (en) 2021-04-06
IL279865A (en) 2021-03-01
WO2020008022A1 (en) 2020-01-09
US20210292434A1 (en) 2021-09-23
CN112543627A (en) 2021-03-23
MX2021000028A (en) 2021-03-09
MX2021000037A (en) 2021-03-25
US20210290534A1 (en) 2021-09-23
AU2019297498A1 (en) 2021-01-21
PE20210779A1 (en) 2021-04-21
SG11202100046UA (en) 2021-02-25
CA3105261A1 (en) 2020-01-09
PE20210462A1 (en) 2021-03-08
CA3105256A1 (en) 2020-01-09
BR112020026789A2 (en) 2021-03-30
IL279868A (en) 2021-03-01
KR20210028673A (en) 2021-03-12
CN112367975A (en) 2021-02-12
AU2019298656A1 (en) 2021-01-28
TW202034898A (en) 2020-10-01
WO2020008035A1 (en) 2020-01-09
JP2021529800A (en) 2021-11-04
AR115713A1 (en) 2021-02-17

Similar Documents

Publication Publication Date Title
SG11202100317YA (en) System and method for the production of biomolecules
IL268470A (en) Method for producing multispecific antibodies
KR102100420B9 (en) Method for producing an exosome that transfers a substance specifically to target and exosome produced by the same method
ZA201908158B (en) Novel method for synthesizing amanitins
EP3504276A4 (en) Lignin pellets and process for producing same
EP4063560C0 (en) Multi-step process for the isolation of components from miscanthus
PL3586344T3 (en) Irradiation targets for the production of radioisotopes and related method of manufacturing
PL3630738T3 (en) Process for the production of ozanimod
IL279868A (en) Method for the production of freeze-dried pellets comprising an anti-coagulation factor xia (fxia) antibody
SG11202002498SA (en) Method of producing an electrocatalyst
EP3563673A4 (en) Method for introducing substance into plant
SI3672770T1 (en) Method for the production of curved furniture components
HUE060390T2 (en) Method for the production of isocyanates in the gasphase
GB2560062B (en) Process for the production of 2-alkylalkanol from an aldehyde
ZA201808424B (en) Method for the manufacture of pelletized nuclear ceramic fuel
RS61783B1 (en) Integrated process for the production of fuel components from glycerin
EP3671762A4 (en) Method of producing the radionuclide nickel-63
EP3847675C0 (en) Process for the production of gallium radionuclides
SG11202013126QA (en) NOVEL HYDROXYPROPYL-ß-CYCLODEXTRIN AND PROCESS FOR THE PRODUCTION THEREOF
HUE060475T2 (en) Process for the production of isocyanates
ZA201906270B (en) An improved method for high level production of crm
HUE050961T2 (en) Method for producing temperature-stable polyalkenamers
DK3577159T3 (en) Process for the production of particles comprising polylactide
IL289210A (en) Method for the production of an antibody
GB201703384D0 (en) Process for the production of Tetraaminobiphenol macrocyclic ligands; and novel Tetraaminobiphenol macrocyclic ligands